Company news
Omeros Corporation (NASDAQ:OMER) news
Omeros Corporation news releases on 6ix. Latest, May 15, 2024: Omeros Corporation Reports First Quarter 2024 Financial Results
Press releases — page 2
Omeros Corporation Reports First Quarter 2024 Financial Results
May 14, 2024
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
May 9, 2024
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
May 8, 2024
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
March 31, 2024
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
March 26, 2024
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
February 19, 2024
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
January 31, 2024
Omeros Corporation Reports Third Quarter 2023 Financial Results
November 8, 2023
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
November 5, 2023
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
November 2, 2023
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
November 1, 2023
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
October 18, 2023
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
October 15, 2023
Omeros Corporation Reports Second Quarter 2023 Financial Results
August 8, 2023
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
August 3, 2023
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
June 11, 2023
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
May 31, 2023
Omeros Corporation Reports First Quarter 2023 Financial Results
May 8, 2023
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
May 3, 2023
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
April 24, 2023
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
April 9, 2023
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
March 12, 2023
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
March 9, 2023
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
March 6, 2023
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
February 5, 2023
Omeros Corporation Reports Third Quarter 2022 Financial Results
November 8, 2022
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
November 7, 2022
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
November 3, 2022
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
October 2, 2022
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
September 14, 2022
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
August 16, 2022
Omeros Corporation Reports Second Quarter 2022 Financial Results
August 8, 2022
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
August 3, 2022
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
July 28, 2022
Omeros Corporation Reports First Quarter 2022 Financial Results
May 9, 2022
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
May 3, 2022
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
April 19, 2022
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
February 28, 2022
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
February 23, 2022
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
January 18, 2022
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
December 22, 2021
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
December 1, 2021
Omeros Corporation Reports Third Quarter 2021 Financial Results
November 8, 2021
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
November 4, 2021
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
November 3, 2021
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
October 17, 2021
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
September 30, 2021
Omeros Corporation Reports Second Quarter 2021 Financial Results
August 8, 2021
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
August 2, 2021
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
June 9, 2021